NASDAQ:CRVS

Corvus Pharmaceuticals Stock Predictions

Healthcare > Biotechnology

Buy CRVS

*Your capital is at risk

$11.60

-0.0900 (-0.770%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

CRVS Prediction Chart

CRVS Predictions History

Latest community submissions for CRVS.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
reliantroofing.263883	Aug 16, 2022	Bullish	$1.08	X	—	0
JS Pro	Mar 31, 2021	$2.99 -2.92%	$3.08	X	97.08%	1
etinobe Amateur	Mar 31, 2021	Bullish	$3.08	X	—	1
sander7100 yo bro Pro @sander7100yobro.167552	Jul 16, 2020	$4.24 +1.44%	$4.18	X	98.56%	2
JS Pro	Jul 16, 2020	$4.14 -0.96%	$4.18	X	99.04%	2
JS Pro	Jul 8, 2020	$4.59 -14.53%	$5.37	X	85.47%	0
tradrjohnson	Jul 8, 2020	Bearish	$5.37	X	—	0
JS Pro	May 13, 2019	$4.40 +4.27%	$4.22	X	95.73%	0
PumpTheseNumbers Pro	May 13, 2019	$4.33 +2.61%	$4.22	X	97.39%	0
joe1234 Pro	May 13, 2019	$4.49 +6.40%	$4.22	X	93.60%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for CRVS with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by